射波刀立体定向放射治疗小肝癌的临床效果

发布时间：2018-01-14 04:24

本文关键词：射波刀立体定向放射治疗小肝癌的临床效果　出处：《临床肝胆病杂志》2017年04期 　论文类型：期刊论文

【摘要】：目的评价小肝癌(s HCC)患者接受射波刀立体定向放射外科治疗的疗效和安全性。方法收集2011年3月-2012年12月解放军第三○二医院行射波刀治疗的28例s HCC患者。射波刀治疗总剂量35~60 Gy/3~5次,连续治疗3~6 d。中位随访时间36个月。依据改良版实体瘤疗效评价标准(mRECIST)进行近期疗效评价,以1、2、3年总生存率和局部控制率作为远期疗效评价指标。采用Kaplan-Meier法分析计算累积生存率和局部控制率。结果 28例患者中,完全缓解17例,部分缓解8例,稳定2例,疾病进展1例,近期有效率89.28%。1、2、3年生存率分别为92.86%、85.71%和78.57%;1、2、3年局部控制率分别为96.43%、92.86%和89.28%。毒性反应主要表现为Ⅰ~Ⅱ级事件。结论射波刀治疗s HCC是安全、有效的,具有较高的局部控制率、生存率和低毒性反应,可以作为不适合手术治疗的s HCC的替代治疗。
[Abstract]:Objective to evaluate small hepatocellular carcinoma (s HCC) in patients with clinical efficacy and safety of CyberKnife stereotactic radiosurgery treatment. 28 cases of s patients with HCC were collected from March 2011 -2012 year in December third, the two hospital of PLA for CyberKnife. CyberKnife treatment for a total dose of 35~60 Gy/3~5 times, continuous treatment for 36 months the follow-up time was 3~6 d.. According to the curative effect of the improved version of evaluation criteria in solid tumors (mRECIST) to evaluate the short-term efficacy, long-term efficacy as the evaluation index to 1,2,3 year overall survival rate and local control rate. Kaplan-Meier method was used to analysis the cumulative survival rate and local control rate. Results in the 28 patients, 17 cases of complete remission, partial remission in 8 cases, 2 cases, 1 cases of disease progression, the short-term effective rate of 89.28%.1,2,3 year survival rates were 92.86%, 85.71% and 78.57%; 1,2,3 year local control rates were 96.43%, 92.86% and 89.28%. toxicity mainly show as I ~ II Conclusion the treatment of s HCC with radiotherapy knife is safe and effective. It has high local control rate, survival rate and low toxic reaction. It can be used as an alternative therapy for s HCC which is not suitable for surgical treatment.

【作者单位】：解放军第三0二医院肿瘤放射治疗中心;
【基金】：首都特色基金(Z151100004015002) 解放军三0二医院院长创新基金(YNKT2014011)
【分类号】：R735.7;R730.55
【正文快照】： 肝细胞癌(HCC)是成人最常见的原发性肝脏肿瘤,是世界第五大常见恶性肿瘤[1]。目前指南[2]推荐肝切除、肝移植和射频消融作为小肝癌(s HCC)的根治性治疗选择。然而由于各种原因,仅有10%~30%的确诊病例能够实施手术切除治疗[3]。同时,供体的缺乏以及严格的适应证使肝移植术亦受

【相似文献】